ABA Home

Patent Docs

RSS Feed

This blawg "focuses on recent developments in biotechnology and pharmaceutical patent law. This weblog offers updates regarding changes in patent office rules and procedures that affect biotech/pharma patent prosecution, provides summaries of recent court decisions that impact biotech/pharma patent litigation and prosecution, and monitors newly filed biotech/pharma patent litigation."

Author: Donald Zuhn and Kevin Noonan are partners at McDonnell Boehnen Hulbert & Berghoff in Chicago; Chris Singer and Sherri Oslick are associates at the firm. Jason Derry is an in-house patent attorney.

Blawg Related Categories: Intellectual Property LawPatent LawScience & Technology LawAssociateIn-house LawyerPartner


Recent Posts from Patent Docs

  • In re Fallaux (Fed. Cir. 2009)

    By Donald Zuhn -- On May 6, the Federal Circuit affirmed a decision by the Board of Patent Appeals and Interferences affirming the final rejection of U.S. Application No. 10/618,526 for obviousness-type double patenting. Appellants…

  • Revision of Procedures Relating to Amending PCT Applications

    By Christopher P. Singer -- In a notice published in the Federal Register on Wednesday, July 1, 2009 (74 Fed. Reg. 31372), the U.S. Patent and Trademark Office published rule changes relating to amendment practice…

  • Biotech/Pharma Docket

    By Suresh Pillai -- Beckman Asks for Dismissal in Patent Dispute with Sequenom Following the completion of a Markman hearing in a dispute with Sequenom Inc. concerning patents covering genotyping methods, Beckman Coulter has asked…

  • FierceBiotech Announces "Fierce 15" for 2009

    By Christopher P. Singer -- FierceBiotech published its annual "Fierce 15" list of what it considers to be among the most promising of the up-and-coming companies in the biotechnology industry. FierceBiotech, a daily biotech industry…

  • Follow-on Biologics in the News - No. 4

    By Donald Zuhn -- IPO Continues to Support 14-Year Exclusivity Period The Intellectual Property Owners Association (IPO), reporting on last week's announcement that the White House believes a 7-year data exclusivity period "strikes the appropriate…

  • USPTO Initiates Patent Prosecution Highway Pilot Program with Finland Patent Office

    By Christopher P. Singer -- In June 29, 2009 press release, the U.S. Patent and Trademark Office announced that it has agreed with the National Board of Patents and Registration of Finland (NBPR) to establish…

  • Court Report

    By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Dey, L.P. et al.…

  • Conference & CLE Calendar

    June 29-30 - Product and Pipeline Enhancement for Generics (Marcus Evans) - Washington, DC July 6, 2009 - Prior Art & Obviousness 2009: The PTO & CAFC Perspective on Patent Law Sections 102 & 103…

  • White House Recommends 7-Year Data Exclusivity Period for Follow-on Biologics

    By Donald Zuhn -- Reuters reports that the White House sent a letter to Rep. Henry Waxman (D-CA), the Chairman of the House Energy and Commerce Committee, on Thursday stating that a follow-on biologics regulatory…

  • Is Venezuela the new Thailand?

    By Kevin E. Noonan -- A great deal has been written over the past week about Venezuela's new patented drug policy. Last Saturday, President Hugo Chavez (at right) announced that his government would "shake up"…


Most Read



Latest Featured Blawgs


How to Submit a Blawg

It's really quite easy actually. Just give us the name, URL and RSS feed to the new blawg and we'll add it to the site if it's not already there.

Submit Now!


Return to top